-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Oncorus, Inc gets an overall score of 1/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US68236R1032 |
Sector | Healthcare |
Industry | Biotechnology |
PE Ratio | None |
---|---|
Dividend Yield | 0.0% |
Beta | 1.95 |
Target Price | 5 |
Market Cap | 3M |
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company develops ONCR-021 for the treatment of non-small cell lung cancer, renal cell carcinoma, melanoma, and anaplastic thyroid cancer; and ONCR-788 for the treatment of small cell lung cancer, neuroendocrine prostate, and other neuroendocrine cancers. Oncorus, Inc. was incorporated in 2015 and is headquartered in Andover, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ONCR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025